Celularity (CELU)
NASDAQ:CELU
Want to see CELU full AI Analyst Report?
CELU Stock Chart & Stats
$1.25
-$0.06(-2.69%)
At close: 4:00 PM EST
$1.25
-$0.06(-2.69%)
Day’s Range― - ―
52-Week Range$0.88 - $4.35
Previous Close$2.13
Volume115.00K
Average Volume (3M)206.82K
Market Cap
$28.49M
Enterprise Value$84.91M
Total Cash (Recent Filing)$6.17M
Total Debt (Recent Filing)$68.16M
Price to Earnings (P/E)―
Beta2.98
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.69
Shares Outstanding28,945,961
10 Day Avg. Volume277,262
30 Day Avg. Volume206,824
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.75
Price to Sales (P/S)1.07
P/FCF Ratio-2.14
Enterprise Value/Market Cap2.98
Enterprise Value/Revenue3.20
Enterprise Value/Gross Profit4.21
Enterprise Value/Ebitda-1.09
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.75
Revenue Forecast (FY)$44.00M
Bulls Say, Bears Say
Bulls Say
NexGel Asset Sale Proceeds & Debt ReductionThe NexGel transaction delivers immediate non-dilutive liquidity and retires roughly $13M of debt, materially easing near-term refinancing pressure. That structural cash infusion and debt reduction can extend runway and reduce financing risk while the company focuses on higher-value programs.
Strategic Refocus On Core Cell Therapy PipelineManagement’s pivot away from biomaterials toward longevity-focused cell therapies concentrates R&D and capital on higher-margin, strategic programs. This structural realignment can improve resource allocation, speed development decisions, and raise long-term value capture if clinical progress follows.
Retains Manufacturing Rights And Royalty UpsideKeeping manufacturing control preserves production expertise and a revenue stream from contract manufacturing plus royalties. That ongoing operational capacity and upside from royalties provide durable margin support and optionality as the company pivots to its core therapeutic programs.
Bears Say
Negative Equity And Elevated LeverageNegative equity and sustained debt levels materially constrain financial flexibility and raise refinancing and covenant default risk. This structural balance-sheet weakness increases the probability of dilutive financings, limits strategic optionality, and persists until meaningful equity restoration occurs.
Ongoing Negative Cash Flow And External Funding RelianceDespite narrowed burn, recurring negative operating and free cash flow mean Celularity remains dependent on external capital or asset sales. That durable funding dependence increases dilution and execution risk for multi-year clinical programs unless sustainable positive cash generation is established.
Volatile, Declining Revenue With Sustained Operating LossesA structural pattern of volatile and declining revenues, combined with persistent operating losses, undermines scalability. Ongoing negative margins require continuous capital to fund development and reduce the company’s ability to self-sustain growth absent a durable reversal in revenue and profitability trends.
Celularity News
CELU FAQ
What was Celularity’s price range in the past 12 months?
Celularity lowest stock price was $0.88 and its highest was $4.35 in the past 12 months.
What is Celularity’s market cap?
Celularity’s market cap is $28.49M.
When is Celularity’s upcoming earnings report date?
Celularity’s upcoming earnings report date is Apr 01, 2027 which is in 330 days.
How were Celularity’s earnings last quarter?
Currently, no data Available
Is Celularity overvalued?
According to Wall Street analysts Celularity’s price is currently Overvalued.
Does Celularity pay dividends?
Celularity does not currently pay dividends.
What is Celularity’s EPS estimate?
Celularity’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Celularity have?
Celularity has 28,945,961 shares outstanding.
What happened to Celularity’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Celularity?
Currently, no hedge funds are holding shares in CELU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Celularity
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy. It also sells and licenses products that are used in surgical and wound care markets, such as Biovance and Interfyl; collects stem cells from umbilical cords and placentas; and provides cells storage under the LifebankUSA brand. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey.
Technical Analysis
Ownership Overview
36.47% Insiders
2.54% Mutual Funds
0.24% Other Institutional Investors
58.44% Public Companies and
Individual Investors